|
|
|
| Effect of Ligustrazine combined with levamlodipine besylate on BNP, Ang Ⅱ and pregnancy outcomes in patients with hypertensive disorders complicating pregnancy |
| WANG Xuefang LU Yanqing▲ |
| Department of Obstetrics, Wuwei People′s Hospital, Gansu Province, Wuwei 733000, China |
|
|
|
Abstract Objective To investigate the effects of Ligustrazine combined with levamlodipine besylate on plasma brain natriuretic peptide (BNP), angiotensin Ⅱ (Ang Ⅱ) and pregnancy outcome in patients with pregnancy-induced hypertension. Methods From January 2016 to January 2018, in Wuwei People′s Hospital, 87 patients with pregnancy-induced hypertension were selected, they were divided into two groups according to whether they used Ligustrazine or not. The control group was given 25% magnesium sulfate and levamlodipine besylate based on symptomatic treatment such as reasonable diet and sedation. The observation group was treated with Ligustrazine on the basis of the control group. BPN, AngⅡ, mean arterial pressure, 24 h urinary protein level, uterine artery, and umbilical artery systolic period the ratio of maximum blood flow velocity to end-diastolic blood flow velocity (S/D), pulse index (PI), and resistance index (RI) before and after treatment were observed, adverse reactions during treatment, treatment effect after treatment 10 d were observed. Follow-up to delivery, the pregnancy outcomes of two groups were observe. Results After treatment, the levels of BNP and AngⅡ in the observation group were lower than before treatment and the control group, the differences were statistically significant (P < 0.05). After treatment, the S/D, PI and RI of the uterine artery and umbilical artery in the observation group were lower than before treatment and the control group, the differences were statistically significant (P < 0.05). The total effective rate in the observation group was higher than the control group, the difference was statistically significant (P < 0.05). The incidence rates of premature labor, cesarean section, intrapartum or postpartum hemorrhage, placental abruption, intrauterine distress and neonatal asphyxia in the observation group were lower than the control group, the differences were statistically significant (P < 0.05). No adverse reactions occurred in both groups during treatment. Conclusion Ligustrazine injection combined with levamlodipine besylate has a satisfactory therapeutic effect on gestational hypertension, reducing the expression of BNP and AngⅡ, increasing uterine and placental blood supply, and reducing the adverse outcomes of pregnancy. It is worthy of clinical promotion.
|
|
|
|
|
|
[1] Snyder SR，Kivlehan SM，Collopy KT. HELLP Syndrome. How to recognize and treat this life-threatening complication of pregnancy [J]. EMS World，2015，44（6）：39-45.
[2] Shopen N，Schiff E，Koren-Morag N，et al. Factors that predict the development of hypertension in women with pregnancy-induced hypertension [J]. Am J Hypertens，2016，29（1）：141-146.
[3] Gandhi M，Jani P，Patel U，et al. Perinatal outcome in pregnancy induced hypertension cases at GMERS Medical College，Dharpur-Patan，North Gujarat region，India：a prospective study [J]. Int J Adv Med，2015，2（2）：152.
[4] 彭静，柳杨.正常妊娠妇女和HDP孕妇妊娠早、中、晚期子宫动脉及其胎儿脐动脉血流动态变化的比较[J].医学综述，2016，22（10）：1996-1998.
[5] Yuan T，Zhang T，Han Z. Placental vascularization alterations in hypertensive disorders complicating pregnancy（HDCP） and smallfor gestational age with HDCP using three-dimensional power doppler in a prospective case control study [J]. BMC Pregnancy Childbirth，2015，15（1）：240.
[6] 孙君侠，李建芬，尹金丽.中药川芎嗪联合硫酸镁治疗妊娠高血压[J].吉林中医药，2015，35（6：）593-595.
[7] 胡小勇，周发春.川芎嗪抑制LPS诱导的人Ⅱ型肺泡上皮细胞炎性反应[J].基础医学与临床，2017，37（6）：839-844.
[8] 谢幸，苟文丽.妇产科学[M]. 8版.北京：人民卫生出版社，2013：3.
[9] Rusavy Z，Pitmva B，Korecko V，et al. Changes in capillary.Diameters in pregnancy-induced hypertension [J]. Hypertension Pregnancy，2015，34（3）：307.
[10] 吴奇兵.苯磺酸左旋氨氯地平片与苯磺酸氨氯地平片治疗妊娠期高血压疾病的疗效对比分析[J].中国妇幼保健，2017，32（13）：2884-2886.
[11] Turpin CA，Sakyi SA，Owiredu WK，et al. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia [J]. BMC Pregnancy Childbirth，2015，15：189.
[12] Minuz P，Fava C，Hao S，et al. Differential regulation of TNF receptors in maternal leukocytes is associated with severe preterm preeclampsia [J]. J Matern Fetal Neonatal Med，2015，28（8）：869-875.
[13] 温丽，郭珍，胡际东，等.血清SOCS-3、TNF-α、IL-16水平及Th1/Th2与妊娠期高血压疾病的关系[J].解放军医学院学报，2017，38（5）：426-429，432.
[14] Mohamed AI，Omar MA，Hammad MA，et al. Development and validation of highly sensitive stability indicating spectrofluorimetric method for determination of amlodipine in pharmaceutical preparations and human plasma [J]. J Fluoresc，2016，26（6）：2141-2149.
[15] 李雪梅，高慧.肼苯哒嗪联合螺内酯治疗产后妊娠高血压性心力衰竭患者的疗效及对血浆脑利钠肽和血管紧张素Ⅱ表达的影响[J].中国妇幼保健，2017，32（7）：1438-1441.
[16] 张勇，贾海玉，李长青，等.血浆脑钠肽与妊娠期高血压疾病、子痫前期的关系[J].中国综合临床，2015，31（6）：484-487.
[17] 巨容，胡旭红，徐若梅，等.妊娠期高血压疾病患者母、胎转化生长因子-β1、血管紧张素Ⅱ及血管内皮生长因子表达水平分析[J].中华妇幼临床医学杂志：电子版，2014，10（6）：774-778.
[18] 韦枫.川芎嗪注射液对老年慢性阻塞性肺疾病急性加重期患者内皮功能和凝血纤溶系统的影响[J].中国医药导报，2017，14（22）：113-116.
[19] 周莹峰.氯吡格雷联合川芎嗪注射液治疗急性脑梗死的临床疗效及对血液流变学的影响[J].中国当代医药，2017，24（30）：86-88.
[20] Easterling TR. Apheresis to treat preeclampsia： insights，opportunities and challenges [J]. J Am Soc Nephrol，2016， 27（3）：663-665.
[21] 李雅萍.川芎嗪联合酚妥拉明治疗妊娠期高血压的临床研究[J].中国基层医药，2017，24（19）：3002-3005.
[22] 曲晓燕，董开杰.川芎嗪注射液联合硫酸镁和酚妥拉明治疗妊娠高血压综合征的临床研究[J].现代药物与临床，2016，31（12）：2017-2020. |
|
|
|
